

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI810674

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Execution Date
ATHYRIUM BUFFALO LP	02/06/2025

**RECEIVING PARTY DATA**

<b>Company Name:</b>	REVANCE THERAPEUTICS, INC
<b>Street Address:</b>	1222 Demonbreun Street, 20th Floor
<b>City:</b>	Nashville
<b>State/Country:</b>	TENNESSEE
<b>Postal Code:</b>	37203

**PROPERTY NUMBERS Total: 56**

Property Type	Number
Application Number:	14803574
Application Number:	13862206
Application Number:	14931329
Application Number:	13141935
Application Number:	16656115
Application Number:	10591732
Application Number:	11072026
Application Number:	13846899
Application Number:	10591486
Application Number:	11073307
Application Number:	12669705
Application Number:	17322901
Application Number:	11367642
Application Number:	11816602
Application Number:	14935886
Application Number:	16140288
Application Number:	11816670
Application Number:	15155551
Application Number:	10793740
Application Number:	10793964

PATENT

Property Type	Number
Application Number:	10446562
Application Number:	10740755
Application Number:	11111951
Application Number:	11709059
Application Number:	12073245
Application Number:	12662186
Application Number:	13132855
Application Number:	14754268
Application Number:	10793739
Application Number:	12010183
Application Number:	11028600
Application Number:	11046721
Application Number:	14796235
Application Number:	16700728
Application Number:	13978673
Application Number:	17114486
Application Number:	15905616
Application Number:	11447984
Application Number:	14852990
Application Number:	17135938
Application Number:	17183934
Application Number:	11617551
Application Number:	12159584
Application Number:	16770033
Application Number:	16643320
Application Number:	12824118
Application Number:	15155341
Application Number:	16175434
Application Number:	14642580
Application Number:	16984036
Application Number:	17472525
Application Number:	17547211
Application Number:	17505454
Application Number:	63151795
PCT Number:	US2123046
PCT Number:	US2154818

**CORRESPONDENCE DATA**

**Fax Number:** 7043311159

***Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***

**Phone:** (704)331-1000

**Email:** jansnider@mvalaw.com,vangambrell@mvalaw.com

**Correspondent Name:** James Van Cleave Gambrell

**Address Line 1:** Moore & Van Allen PLLC

**Address Line 2:** 100 North Tryon Street, Suite 4700

**Address Line 4:** Charlotte, NORTH CAROLINA 28202

<b>ATTORNEY DOCKET NUMBER:</b>	036251-000309
--------------------------------	---------------

<b>NAME OF SUBMITTER:</b>	Jan Snider
---------------------------	------------

<b>SIGNATURE:</b>	/Jan Snider/
-------------------	--------------

<b>DATE SIGNED:</b>	02/07/2025
---------------------	------------

**Total Attachments: 5**

source=Release of Security Interest in Patents - Revance (Executed) (13979618.1)#page1.tiff

source=Release of Security Interest in Patents - Revance (Executed) (13979618.1)#page2.tiff

source=Release of Security Interest in Patents - Revance (Executed) (13979618.1)#page3.tiff

source=Release of Security Interest in Patents - Revance (Executed) (13979618.1)#page4.tiff

source=Release of Security Interest in Patents - Revance (Executed) (13979618.1)#page5.tiff

## TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS

This TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS, dated as of February 6, 2025 (this “Release”), is made by ATHYRIUM BUFFALO LP, a Delaware limited partnership, as Administrative Agent (the “Administrative Agent”), in favor of REVANCE THERAPEUTICS, INC., a Delaware corporation (“Company”).

**WHEREAS**, pursuant to that certain Security Agreement, dated as of March 18, 2022 (as the same may be amended, modified, restated or supplemented from time to time, the “Security Agreement”), by and among the Company and the Administrative Agent for the Secured Parties referenced therein, the Company granted a continuing security interest in and continuing lien upon, the patents, patent licenses and patent applications set forth on Schedule 1 attached hereto to the Administrative Agent for the ratable benefit of the Secured Parties; and

**WHEREAS**, pursuant to the Security Agreement, the Company executed and delivered to Administrative Agent the Notice of Grant of Security Interest in Patents, dated as of March 18, 2022 (the “Notice”), which was recorded at the United States Patent and Trademark Office (“USPTO”) on March 18, 2022, at Reel 059437 Frame 0654.

**NOW THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent and Company agree as follows:

**SECTION 1. Defined Terms.** All capitalized terms used herein but not otherwise defined herein have the meanings given to them in the Security Agreement or in the Notice.

**SECTION 2. Termination and Release.** Administrative Agent, without representation, warranty, or recourse, hereby:

(a) terminates, cancels, discharges, and releases the continuing security interest in and continuing lien upon, the patents, patent licenses and patent applications set forth on Schedule 1; and

(b) authorizes the recordation of this Release with the USPTO at Company’s expense.

**SECTION 3. Choice of Law.** This Release and obligations of the parties hereunder, and all of their successors, assigns, and transferees, shall be governed by and construed in accordance with the laws of the State of New York.


[Remainder of Page Intentionally Left Blank.]

**IN WITNESS WHEREOF**, the Administrative Agent has caused this Release to be duly executed as of the date first set forth above.

ADMINISTRATIVE AGENT:

ATHYRIUM BUFFALO LP,  
a Delaware limited partnership

By: ATHYRIUM OPPORTUNITIES ASSOCIATES IV  
CO-INVEST LLC, its general partner

By:    
FD1D4536844A4B2...  
Name: Rashida Adams  
Title: Authorized Signatory

## Schedule 1

### Patents:

Application Number	Patent Number	Filing Date	Title
US14803574	US9901627B2	July 20, 2015	Topical Ocular Preparation of Botulinum Toxin for Use in Ocular Surface Disease
US13862206	US9393291B2	April 12, 2013	Use of Botulinum Toxin for the Treatment of Cerebrovascular Disease, Renovascular and Retinovascular Circulatory Beds
US14931329	US10857215B2	November 3, 2015	Use of Botulinum Toxin for the Treatment of Cerebrovascular Disease, Renovascular and Retinovascular Circulatory Beds
US13141935	US9956435B2	July 19, 2011	Injectable Botulinum Toxin Formulations
US16656115		October 17, 2019	INJECTABLE BOTULINUM TOXIN FORMULATIONS
US10591732	US8398997B2	September 26, 2007	Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
US11072026	US8404249B2	March 3, 2005	Compositions and methods for topical application and transdermal delivery of botulinum toxins
US13846899	US9211248B2	March 18, 2013	Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
US10591486	US8974774B2	June 18, 2007	Compositions and Methods for Topical Diagnostic and Therapeutic Transport
US11073307	US8092788B2	March 3, 2005	Compositions and methods for topical diagnostic and therapeutic transport
US12669705	US8623811B2	February 3, 2010	ANTIMICROBIAL PEPTIDE, COMPOSITIONS, AND METHODS OF USE
US17322901		May 18, 2021	Albumin-Free Botulinum Toxin Formulations
US11367642	US9180081B2	March 3, 2006	Compositions and methods for topical application and transdermal delivery of botulinum toxins
US11816602	US9314416B2	October 6, 2008	Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
US14935886	US10080786B2	November 9, 2015	COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINS
US16140288	US10744078B2	September 24, 2018	COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINS
US11816670	US8580317B2	July 1, 2009	Compositions and Methods for Treating Acne
US15155551	US10201594B2	May 16, 2016	Compositions and Methods for Safe Treatment of Rhinitis
US10793740	US7670608B2	March 8, 2004	Selection of patients with increased responsiveness to botulinum toxin
US10793964	US8691769B2	March 8, 2004	Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections
US10446562	US7459164B2	May 28, 2003	Composition for therapeutic and cosmetic botulinum toxin
US10740755	US7491403B2	December 22, 2003	Pharmaceutical botulinum toxin compositions
US11111951	US7691394B2	April 22, 2005	High-potency botulinum toxin formulations
US11709059	US8580745B2	February 22, 2007	Composition for therapeutic and cosmetic botulinum toxin
US12073245	US8241640B2	March 3, 2008	Pharmaceutical botulinum toxin compositions
US12662186	US8679486B2	April 5, 2010	High-potency botulinum toxin formulations
US13132855	US9066851B2	October 28, 2011	Extended Length Botulinum Toxin Formulation for Human or Mammalian Use
US14754268	US9950042B2	June 29, 2015	Extended Length Botulinum Toxin Formulation for Human or Mammalian Use
US10793739	US7335367B2	March 8, 2004	Treatment of chronic chalazion and hordeolum with botulinum toxin
US12010183	US7943152B2	January 22, 2008	Treatment of chronic chalazion and hordeolum with botulinum toxin

Application Number	Patent Number	Filing Date	Title
US11028600	US7270826B2	January 5, 2005	Methods of using botulinum toxin for the treatment of hypervolemic lip deformity (lip ectropion)
US11046721	US8192979B2	February 1, 2005	Compositions, methods and devices for preparing less painful Botulinum toxin formulations
US14796235	US9469849B2	July 10, 2015	Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
US16700728		December 2, 2019	Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
US13978673		February 10, 2014	METHODS AND KITS FOR TOPICAL APPLICATION, REMOVAL, AND INACTIVATION OF THERAPEUTIC OR COSMETIC TOXIN COMPOSITIONS
US17114486		December 7, 2020	METHODS AND KITS FOR TOPICAL APPLICATION, REMOVAL, AND INACTIVATION OF THERAPEUTIC OR COSMETIC TOXIN COMPOSITIONS
US15905616		February 26, 2018	Topical Ocular Preparation of Botulinum Toxin for Use in Ocular Surface Disease
US11447984	US8926991B2	June 7, 2006	Botulinum toxin and the treatment of primary disorders of mood and affect
US14852990	US10441641B2	September 14, 2015	Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US17135938		December 28, 2020	Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US17183934		February 24, 2021	BOTULINUM TOXIN AND THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT
US11617551	US8815954B2	December 28, 2006	Arginine Heteromers for Topical Administration
US12159584	US8628756B2	October 7, 2008	Arginine Heteromers for Topical Administration
US16770033		June 4, 2020	INJECTABLE BOTULINUM TOXIN FORMULATIONS AND METHODS OF USE THEREOF HAVING HIGH RESPONSE RATE AND LONG EFFECT DURATION
US16643320		February 28, 2020	TRANSMUCOSAL BOTULINUM TOXIN COMPOSITIONS, KITS, AND METHODS FOR TREATING BLADDER DISORDERS
US12824118	US9340587B2	June 25, 2010	ALBUMIN-FREE BOTULINUM TOXIN FORMULATIONS
US15155341	US10111939B2	May 16, 2016	Albumin-Free Botulinum Toxin Formulations
US16175434		October 30, 2018	Albumin-Free Botulinum Toxin Formulations
PCT/US2021/023046		March 18, 2021	INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES
US14642580	US10172877	March 9, 2015	COMPOSITIONS AND METHODS FOR TOPICAL DIAGNOSTIC AND THERAPEUTIC TRANSPORT
US16984036		March 30, 2010	METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS ASSOCIATED WITH VASCULAR HYPER-REACTIVITY
US17472525		September 10, 2021	INJECTABLE BOTULINUM TOXIN FORMULATIONS AND METHODS OF USE THERE OF HAVING LONG DURATION OF THERAPEUTIC OR COSMETIC EFFECT
US17547211		December 9, 2021	METHODS OF TREATMENT FOR CERVICAL DYSTONIA
US17505454		October 19, 2021	BOTULINUM TOXIN AND THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT
US63151795		February 21, 2021	METHODS OF TREATING UPPER LIMB SPASTICITY WITH BOTULINUM TOXIN
PCT/US21/54818		October 13, 2021	METHODS FOR TREATING CERVICAL DYSTONIA
US17100806		November 20, 2020	COMPOSITIONS AND METHODS FOR TOPICAL DIAGNOSTIC AND THERAPEUTIC TRANSPORT
US17951220		September 23, 2022	INJECTABLE BOTULINUM TOXIN FORMULATIONS

Application Number	Patent Number	Filing Date	Title
US17234690		April 19, 2021	BOTULINUM TOXIN AND THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND EFFECT
US16761432		May 4, 2020	BOTULINUM TOXIN FORMULATIONS AND METHODS OF USE THEREOF IN PLANTAR FASCIITIS
US17912513		March 18, 2021	INJECTIBLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES
PCT/US2022/017170		February 21, 2022	METHODS OF TREATING UPPER LIMB SPASTICITY WITH BOTULINUM TOXIN
US16681052		January 14, 2019	BOTULINUM TOXIN AND THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND EFFECT